Pion S, Christianson G J, Fontaine P, Roopenian D C, Perreault C
Research Center, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada; and The Jackson Laboratory, Bar Harbor, ME, USA.
Blood. 1999 Feb 1;93(3):952-62.
The immunodominance effect, whereby the presence of immunodominant epitopes prevents recognition of nondominant determinants presented on the same antigen-presenting cell (APC) considerably restricts the repertoire of cytotoxic T lymphocyte (CTL) responses. To elucidate the molecular basis of the immunodominance effect, we compared the interactions of a dominant (B6(dom1)) and a nondominant epitope (H-Y) with their restricting class I molecule (H2-Db), and their ability to trigger cognate CTLs. We found that B6(dom1)/Db complexes behaved as optimal T-cell receptor (TCR) ligands and triggered a more rapid in vivo expansion of cognate CTLs than H-Y/Db complexes. The superiority of the dominant epitope was explained by its high cell surface density (1,012 copies/cell for B6(dom1) v 10 copies/cell for H-Y) and its optimal affinity for cognate TCRs. Based on these results, we conclude that dominant class I-associated epitopes are those that have optimal ability to trigger TCR signals in CTLs. We propose that the rapid expansion of CTLs specific for dominant antigens should enable them to compete more successfully than other CTLs for occupancy of the APC surface.
免疫显性效应,即免疫显性表位的存在会阻止对同一抗原呈递细胞(APC)上呈递的非显性决定簇的识别,这在很大程度上限制了细胞毒性T淋巴细胞(CTL)反应的库。为了阐明免疫显性效应的分子基础,我们比较了一个显性表位(B6(dom1))和一个非显性表位(H-Y)与其限制性I类分子(H2-Db)的相互作用,以及它们触发同源CTL的能力。我们发现,B6(dom1)/Db复合物表现为最佳的T细胞受体(TCR)配体,并且比H-Y/Db复合物在体内触发同源CTL的扩增更快。显性表位的优势在于其高细胞表面密度(B6(dom1)为1012个拷贝/细胞,而H-Y为10个拷贝/细胞)以及对同源TCR的最佳亲和力。基于这些结果,我们得出结论,显性I类相关表位是那些在CTL中具有最佳触发TCR信号能力的表位。我们提出,针对显性抗原的CTL的快速扩增应使它们比其他CTL更成功地竞争占据APC表面。